According to a recent LinkedIn post from Medmain Inc, the company is highlighting research on an AI model designed to automatically detect Ki-67-positive cells and calculate the labeling index in immunohistochemical digital slides. The post notes that the model’s results were closely aligned with pathologists’ evaluations and that the work has been published in the MDPI journal Diagnostics, with support from a Fukuoka Prefecture medical device R&D grant.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests that Medmain is advancing the technical capabilities of its digital pathology support solution, PidPort, by incorporating cell-level classification on whole-slide images. For investors, this type of peer-reviewed validation may strengthen Medmain’s credibility in clinical AI, potentially enhancing competitive positioning in digital pathology and supporting future commercialization or partnership opportunities in oncology diagnostics.
The publication in a recognized journal could make it easier for Medmain to engage with hospitals, laboratories, and potential strategic partners that require evidence-based solutions. While the post does not provide commercial timelines or revenue guidance, successful deployment of automated Ki-67 assessment may expand the addressable market for PidPort in immunohistochemistry workflows and could support longer-term monetization in precision medicine and pathology AI segments.